New drug combo aims to block Cancer's growth signals
NCT ID NCT07446725
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental oral drugs, GH55 and GH21, taken together by people with advanced solid tumors that have a specific genetic change in the MAPK pathway. The trial has two phases: first, to find the safest dose (Phase 1), and then to see if the combination can shrink tumors or slow their growth (Phase 2). About 152 participants who have exhausted standard treatments will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GH55 and GH21 capsules (oral drugs that block cancer growth signals)
What this could lead to
If this works, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early, small study (Phase 1/2) focused on safety and dosing, so it is not yet known if the combination will be effective. Side effects are possible, and the drugs may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Goboard Cancer Hospital
Shanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••